TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06141694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The LIBERTY® Robotic System
Description: The LIBERTY® Robotic System is intended for use in the remote delivery and manipulation of guidewires and catheters, and remote manipulation of guide catheters, to facilitate navigation to anatomical targets in the peripheral vasculature.~The LIBERTY® Robotic System is not intended for coronary or neurointerventional procedures.
Study: NCT05282797

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT06363877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: Peritoneal lavage: With the fascia open, the peritoneum will be washed out with 1L of dilute aqueous povidone-iodine solution allowing the solution to sit in the peritoneum for 2 minutes. This is followed by suctioning of the povidone-iodine solution then wash-out with 2L of normal saline followed by suctioning of the normal saline.~Wound Irrigation: With the fascia closed, the wound will be irrigated with 500mL povidone-iodine solution, suctioned, then washed-out with 500 mL normal saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Peritoneal lavage: With the fascia open, the peritoneum will be washed out with 1L of normal saline allowing the solution to sit in the peritoneum for 2 minutes. This is followed by suctioning of the solution, wash-out with 2L of normal saline, followed by suctioning of the normal saline.~Wound Irrigation: With the fascia closed, the wound will be irrigated with 500mL normal saline solution, suctioned, then washed-out with 500 mL normal saline.
Study: NCT06527313

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Special Exercises
Description: Subjects in the control group will be shown home exercises customized for knee osteoarthritis and asked to continue them.~Specialized Home Exercises for the Knee Joint~1. Lumbar extensor stretching, Hamstring stretching, hip flexors stretching, TFL stretching,~2. Straight leg raise (lying on back and side)~3. Bridge exercise~4. Drawing circles while lying on your back and side~5. Knee flexion-extension~6. Weight bearing exercises~7. Tiptoe exercise~8. Step climbing and descending exercise~9. Terminal knee extension~10. Strengthening the muscles around the hips
Study: NCT04799210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eximis CS (Contained Segmentation) System
Description: Containment, segmentation and extraction of uterine tissue in pre-menopausal women undergoing laparoscopic hysterectomy or myomectomy for non-cancer indications.
Study: NCT05282797

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT05698446

Intervention type: PROCEDURE
Intervention: Modified Broström + Suture tape augmentation operation
Description: Patients with CLAI and GJL will accept the Modified Broström + Suture tape augmentation operation

Intervention type: PROCEDURE
Intervention: Anatomic reconstruction operation
Description: Anatomic reconstruction operation
Study: NCT06363929

Intervention type: DEVICE
Intervention: Dexcom G6 continuous glucose monitor
Description: Dexcom G6 continuous glucose monitor to be placed on neonates with hyperinsulinism for 10 days.
Study: NCT06022757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW5004
Description: XNW5004 an EZH2 inhibitor, BID, administered in continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW5004
Description: XNW5004 an EZH2 inhibitor, BID, administered in continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW5004
Description: XNW5004 an EZH2 inhibitor, BID, administered in continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW5004
Description: XNW5004 an EZH2 inhibitor, BID, administered in continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW5004
Description: XNW5004 an EZH2 inhibitor, BID, administered in continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW5004
Description: XNW5004 an EZH2 inhibitor, BID, administered in continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW5004
Description: XNW5004 an EZH2 inhibitor, BID, administered in continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection
Description: KEYTRUDA® (pembrolizumab) a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection
Description: KEYTRUDA® (pembrolizumab) a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection
Description: KEYTRUDA® (pembrolizumab) a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection
Description: KEYTRUDA® (pembrolizumab) a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection
Description: KEYTRUDA® (pembrolizumab) a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection
Description: KEYTRUDA® (pembrolizumab) a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection
Description: KEYTRUDA® (pembrolizumab) a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
Study: NCT04779970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cessation of ongoing treatment
Description: Cessation of ongoing treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cessation of ongoing treatment
Description: Cessation of ongoing treatment
Study: NCT05226455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax + azacitidine +/- donor lymphocyte infusion
Description: Venetoclax will be given once daily orally on days 1 to 14 for all cycles. Venetoclax + azacitidine +/- donor lymphocyte infusion (12 cycles maximum)
Study: NCT05199779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Session Intervention Leveraging an Ultra-Brief Self-Compassion Exercise
Description: This 20-second contemplative exercise includes draws from the science of habit formation and includes elements of self-soothing touch, somatic experiencing, and mindful self-compassion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Finger-Tapping Active Control
Description: This 20-second finger tapping exercise involves touching each finger to the thumb on one hand and repeating for twenty seconds. This intervention was designed to control for the potential effect of assessment on outcomes, the effect of having an activity to do for the duration of the intervention (4 weeks), regression to the mean, time, or other nonspecific factors.
Study: NCT05061316

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nestlé Impact Advanced Recovery
Description: Immunonutrition drink that helps support the immune system: reduces risk of prolonged hospital stay and complications after surgery.
Study: NCT05333406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN001
Description: EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10\^5 cells/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN001
Description: EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group B (High dose): 2.5x10\^6 cells/kg
Study: NCT04899882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KinHémo
Description: Evaluation and cardiovascular training, combination of resistance and flexibility training
Study: NCT05154682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 5 mg Oral Tablet
Description: Oxycodone will be given every 4 hours as needed for 2 weeks after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 5 mg Oral Tablet
Description: Oxycodone will be given every 4 hours as needed for 2 weeks after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 500Mg Tab
Description: Acetaminophen will be taken every 4 hours for 2 weeks after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen 500 Mg
Description: Naproxen will be taken every 12 hours for 2 weeks after surgery
Study: NCT06514144

Intervention type: DRUG
Intervention: BGF
Description: budesonide/glycopyrrolate/formoterol fumarate
Study: NCT04945317

Intervention type: OTHER
Group type: OTHER
Intervention: ROSE (presence of cytotech) & liquid prep
Description: Standard of care EBUS will include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is liquid.

Intervention type: OTHER
Group type: OTHER
Intervention: NO-ROSE (absence of cytotech) & liquid prep
Description: Standard of care EBUS will NOT include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is liquid.

Intervention type: OTHER
Group type: OTHER
Intervention: ROSE (presence of cytotech) & tissue clot sample
Description: Standard of care EBUS will include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is a tissue clot.

Intervention type: OTHER
Group type: OTHER
Intervention: NO-ROSE (absence of cytotech) & tissue clot sample
Description: Standard of care EBUS will NOT include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is a tissue clot.
Study: NCT05148325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT4706
Description: The administration cycle was proposed to be 3 weeks (Q3W), i.e., 21 days in a cycle, and the first 4 cycles were administered on the first day of each cycle.
Study: NCT05766514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Subjects will be given 5 mg/m2 cladribine intravenously on days 1-5 of cycle 1 and on days 1-3 of cycles 2, 5, 6, 9, 10, 13, 14, 17 and 18.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Subjects will be given 20 mg cytarabine subcutaneously twice daily on days 1-10 of cycles 1, 2, 5, 6, 9, 10, 13, 14, 17 and 18.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Subjects will be given 20 mg/m2 decitabine intravenously on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15 and 16

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azacitidine or decitabine
Description: Subjects will be given either 20 mg/m2 decitabine intravenously on days 1-5 of each cycle or 75 mg/m2 azacitidine intravenously or subcutaneously on days 1-7 of each cycle. The treating physician will determine which drug each subject will receive.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Subject will take 400 mg venetoclax orally once daily on days 1-21 of each cycle.
Study: NCT04977050

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quidel quickvue antigen test for COVID-19
Description: rapid antigen test on nasal swab specimen for COVID-19
Study: NCT05807451

Intervention type: PROCEDURE
Intervention: High Tibial Osteotomy (Uniplanar and Biplanar )
Description: High Tibial Osteotomy using monoplanar and biplanar osteotomy techniques

Intervention type: PROCEDURE
Intervention: High Tibial Osteotomy (Uniplanar and Biplanar )
Description: High Tibial Osteotomy using monoplanar and biplanar osteotomy techniques
Study: NCT05600374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bossdevice
Description: The bossdevice is a real-time digital signal processor consisting of hardware and software algorithms. It is designed to read-in a real-time raw data stream from a bio-signal amplifier (electroencephalography, EEG), to continuously analyze this data and to detect patterns based on oscillations in different frequencies. When such a specific bio-signal pattern is detected, the device indicates this through a standard output port. This enables a connected device to know with millisecond accuracy when a specific biosignal pattern occurs.
Study: NCT05566665

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of blood and bronchoalveolar samples to study Pharmacokinetics of ceftazidime/avibactam, meropenem/varbobactam, ceftolozane/tazobactam, or cefiderocol
Description: The antibiotic treatment with ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol will follow the standard clinical practice.~The concentration of ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol will be measured at specific timepoints in plasma samples and bronchoalveolar lavage samples, and a PK analysis and modeling will be carried out .
Study: NCT05724251

Intervention type: OTHER
Intervention: healthy
Description: no intervention
Study: NCT06310291

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VTP-1000
Description: Intramuscular (IM) injection comprised of self-assembling nanoparticles of gluten peptides and a rapamycin component

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VTP-1000
Description: Intramuscular (IM) injection comprised of self-assembling nanoparticles of gluten peptides and a rapamycin component

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VTP-1000
Description: Intramuscular (IM) injection comprised of self-assembling nanoparticles of gluten peptides and a rapamycin component

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VTP-1000
Description: Intramuscular (IM) injection comprised of self-assembling nanoparticles of gluten peptides and a rapamycin component

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VTP-1000
Description: Intramuscular (IM) injection comprised of self-assembling nanoparticles of gluten peptides and a rapamycin component

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VTP-1000
Description: Intramuscular (IM) injection comprised of self-assembling nanoparticles of gluten peptides and a rapamycin component

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: Intramuscular (IM) injection comprised of saline solution
Study: NCT05724251

Intervention type: OTHER
Intervention: periodontitis
Description: no intervention
Study: NCT06310291

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: Intramuscular (IM) injection comprised of saline solution
Study: NCT06580288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone
Description: 10mg or 20mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10mg or 20mg
Study: NCT06579209

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide adenine dinucleotide
Description: Participants will take a supplement for four weeks. The supplement will either be Nicotinamide adenine dinucleotide or a placebo
Study: NCT04644042

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glenohumeral arthroscopy + Arthroscopic Subacromial Decompression
Description: In addition to the glenohumeral athroscopy a lateral portal will be used to access the subacromial space. The subacromial space will be decompressed with removal of inflamed bursal tissue and acromioclavicular osteophytes, release of the coracoacromial ligament, and, if deemed necessary by the surgeon, acromioplasty performed ad modum Caspari.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glenohumeral arthroscopy + lateral skin incision
Description: Glenohumeral arthroscopy is performed as a standard investigational procedure. The patient is put under general anesthesia and positioned in the 'beach chair position'. An anteriorsuperior portal and a posterior mid-glenoid portal are used as entry to the joint. The following structures are investigated as a minimum: the articular surface of the humeral head and the glenoid, labrum, the long biceps tendon and its attachment at the superior labrum, the undersurface of the supraspinatus and the infraspinatus tendon, the subscapularis tendon and the glenohumeral ligaments. To allow for the best possible blinding a skin incision (mimicking the one used for arthroscopic subacromial decompression) is performed on the lateral side of the shoulder of the participants in the control group. The obturator is introduced in the subcutaneous tissue and a slight circular release is performed. The deltoid fascia is not perforated and the subacromial space is not entered.
Study: NCT05191758

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FPP supplement
Description: Participants will take the supplements per randomization

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FPP supplement
Description: Participants will take the supplements per randomization

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FPP supplement
Description: Participants will take the supplements per randomization
Study: NCT06213948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 MG
Description: Mirtazapine~* Commercial name: Remeron® SolTab~* Pharmaceutical form: film-coated tablets (15 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 MG
Description: Mirtazapine~* Commercial name: Remeron® SolTab~* Pharmaceutical form: film-coated tablets (15 mg)
Study: NCT05550454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic Mechanical Ventilation
Description: Ventilation settings:~Mode: (S)Continuous Mandatory Ventilation Rate: 10 b/min. Tidal Volume: 500 ml (male), 450 ml (female) I:E=1:1 Positive end expiratory pressure (PEEP): 5 cmH2O Flow trigger: off Oxygen: 100% Alarms: Pressure 70 cmH20, Tidal volume 100 \~ 1,000 ml

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Ventilation
Description: Ambu-bagging (It is recommended in the guidelines as a ventilation method.) Methods: 10 times per minutes by medical personnel
Study: NCT05518240

Intervention type: DEVICE
Intervention: Stent Retrievers
Description: Procedure: Embotrap device

Intervention type: DEVICE
Intervention: Stent Retriever
Description: Procedure: Solitaire device
Study: NCT05210556

Intervention type: OTHER
Intervention: Diagnosed with Surgical Site Infection
Description: As an observational study, this notates patients who were diagnosed with a deep organ/space surgical site infection within 30 days of surgery
Study: NCT04813575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryo lung biopsies
Description: Bronchoscopic lung biopsy utilizing the cryo technique
Study: NCT06303583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel, 50 mg/m2, QW\*5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: area under the curve of2mg/mL/min, QW\*5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: 200mg Q3W, 2cycles
Study: NCT06184204

Intervention type: DRUG
Intervention: Trombix® (Rivaroxaban)
Description: 20mg or 15 mg as per the doctor's prescription
Study: NCT06482190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSN0402 Part 1
Description: Participants will receive single ascending doses of 2mg, 4mg, 8mg, 12 mg, and 16mg of RSN0402 or placebo on Day 1 for Cohort 1 to 5. Cohort 2(4mg) will also a single dose of 150 mg nintedanib soft capsule will be administered orally after at least 7-days washout period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSN0402 Part 2
Description: Participants will receive multiple ascending doses of 4mg ,8mg,12mg ,16mg of RSN0402 or placebo administered once daily from Day 1 to Day 7 for Cohort 6 to 9.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo across Part 1 and Part 2 of the study.
Study: NCT05704998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Posture exercises, myofascial release techniques, sternocleidomastoideus and upper trapezius kinesio taping, trigger point ischemic compression, suboccipital release technique, cervical traction, deep neck flexors endurance exercises, massage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Posture exercises, myofascial release techniques, sternocleidomastoideus and upper trapezius kinesio taping, trigger point ischemic compression, suboccipital release technique, cervical traction, deep neck flexors endurance exercises, massage
Study: NCT06129435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visuospatial Task (VST)
Description: Participants randomized to the VST condition will play a visuospatial game (i.e., Tetris). Participants will be given two minutes to practice Tetris and then will be instructed to play for 15 minutes without stopping.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Word Association Task (WAT)
Description: Participants randomized to the WAT condition will play a word association game. Research staff members will read from a list of 300 words, not associated with trauma, to the participant. The participant will verbally respond to each word out loud with the first word that comes to their mind. This word association task will continue for 15 minutes or until all 300 words are read, whichever occurs first.
Study: NCT06303583

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 41.4Gy in 23 fractions
Study: NCT04951128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: Tranexamic acid (100 mg/mL concentration; 0.5 mL) will be added to local anesthetic mixture of 2% lidocaine with epinephrine (2.25 mL) and 0.5% bupivacaine with epinephrine (2.25mL).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic control
Description: Local anesthetic mixture without tranexamic acid consisting of 2% lidocaine with epinephrine (2.5 mL) and 0.5% bupivacaine with epinephrine (2.5 mL).